GAITHERSBURG, Md. - A panel of experts Wednesday narrowly backed the approval of Dyax Corp.'s Kalbitor (ecallantide, DX-88) to treat acute attacks of hereditary angioedema (HAE), a rare, genetic disorder, despite the drug's potential to cause severe allergic reactions and a lack of robust study data. (BioWorld Today)